CompletedPhase 2NCT00109967
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Stephen Ansell, M.DNorth Central Cancer Treatment Group
- Intervention
- rituximab(biological)
- Enrollment
- 71 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2012
Study locations (30)
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- The Medical Center of Aurora, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- Saint Anthony Central Hospital, Denver, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Exempla Saint Joseph Hospital, Denver, Colorado, United States
- Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- Colorado Cancer Research Program CCOP, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- Longmont United Hospital, Longmont, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00109967 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center